# Ocugen clinical trial results and market performance

> Live situation record from CLSTR: https://clstr.news/situations/ocugen-clinical-trial-results-and-market-performance
> Updated: 2026-09-30T00:00:00.000Z. Sources: 6. Developments: 2.

Ocugen experienced significant market volatility following an interim analysis of its OCU410ST gene therapy study for Stargardt disease. Data from the first 26 participants indicated a “negative treatment effect,” causing the company’s stock to drop approximately 21 percent within a week. Despite these results, an independent data monitoring committee recommended continuing the study for another eight months, noting the current data set was insufficient for a definitive conclusion.

By late September, analysts at HC Wainwright raised their FY2026 earnings estimates for Ocugen, forecasting earnings of ($0.27) per share, an improvement from the previous ($0.28) forecast.

## Timeline

### 2026-09-30: Ocugen earnings estimates raised as Oculis board member resigns

HC Wainwright raised FY2026 earnings estimates for Ocugen, Inc., while Oculis Holding AG announced the resignation of board director Lionel Carnot.

3 sources. https://clstr.news/cluster/ocugen-earnings-estimates-raised-as-oculis-board-member-resigns

### 2026-09-10: Ocugen stock drops following negative interim Stargardt disease trial data

Ocugen's stock fell 21% following an interim analysis of its Stargardt disease gene therapy study showing a negative treatment effect, though the clinical trial will continue for eight more months.

4 sources. https://clstr.news/cluster/ocugen-stock-drops-following-negative-interim-stargardt-disease-trial-data

---
Cite as: Ocugen clinical trial results and market performance. CLSTR, https://clstr.news/situations/ocugen-clinical-trial-results-and-market-performance